Aspirin and other NSAIDs as chemoprevention agents in melanoma.
Aspirin and other NSAIDs as chemoprevention agents in melanoma.
复制标题
DOI：
10.1158/1940-6207.capr-14-0018
复制
发表时间：
2014-06
期刊：
影响因子：
--
通讯作者：
Grossman D
中科院分区：
文献类型：
--
作者：
Goodman JR;Grossman D
黑色素瘤的发病率正在增加，尽管最近在治疗上取得了进展，但转移性疾病患者的预后仍然很差。因此，早期发现和化学预防是改善患者预后的有前景的策略。阿司匹林(ASA)和其他非类固醇抗炎药(NSAIDs)已经在其他几种癌症中显示出化学保护活性，并已被建议作为黑色素瘤的化学预防药物。然而，在过去的十年里，一些关于非甾体抗炎药和黑色素瘤风险的病例对照、前瞻性和干预性研究都产生了相互矛盾的结果。这些不一致的发现导致了非类固醇抗炎药在黑色素瘤化学预防中的临床应用的不确定性。这篇简短的综述重点介绍了非甾体抗炎药的作用机制和治疗黑色素瘤的原理，对先前研究的结果和局限性进行了比较回顾，并讨论了在证明这些药物是降低黑色素瘤风险的有效药物方面的未来挑战。
Melanoma incidence is increasing and, despite recent therapeutic advances, the prognosis for patients with metastatic disease remains poor. Thus early detection and chemoprevention are promising strategies for improving patient outcomes. Aspirin (ASA) and other non-steroidal anti-inflammatory drugs (NSAIDs) have demonstrated chemoprotective activity in several other cancers, and have been proposed as chemopreventive agents for melanoma. Throughout the last decade, however, a number of case-control, prospective, and interventional studies of NSAIDs and melanoma risk have yielded conflicting results. These inconsistent findings have led to uncertainty about the clinical utility of NSAIDs for melanoma chemoprevention. This mini-review highlights current knowledge of NSAID mechanisms of action and rationale for use in melanoma, provides a comparative review of outcomes and limitations of prior studies, and discusses the future challenges in demonstrating that these drugs are effective agents for mitigating melanoma risk.